Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ironwood Pharmaceuticals

0.6099
-0.0121-1.95%
Volume:2.15M
Turnover:1.32M
Market Cap:98.69M
PE:-3.02
High:0.6386
Open:0.6220
Low:0.5940
Close:0.6220
Loading ...

Ironwood Pharmaceuticals Faces Nasdaq Delisting Risk Over Minimum Bid Price Non-Compliance

Reuters
·
13 hours ago

CEO Thomas A. McCourt Reports Disposal of Common Shares in Ironwood Pharmaceuticals Inc

Reuters
·
21 May

Ironwood Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May

Ironwood Pharmaceuticals Q1 Adj. EPS $(0.14) Misses $(0.05) Estimate, Sales $41.14M Miss $45.98M Estimate

Benzinga
·
07 May

BRIEF-Ironwood Pharmaceuticals Q1 Revenue USD 41.143 Million Vs. IBES Estimate USD 46 Million

Reuters
·
07 May

Ironwood Pharmaceuticals Inc: Qtrly Adj Shr Loss $0.14

THOMSON REUTERS
·
07 May

Ironwood Pharmaceuticals Q1 Adjusted Ebitda USD -4.742 Million

THOMSON REUTERS
·
07 May

Ironwood Pharmaceuticals Inc expected to post a loss of 1 cent a share - Earnings Preview

Reuters
·
05 May

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Business Wire
·
01 May

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ironwood Pharma (IRWD), AbbVie (ABBV) and Molecular Partners (MOLN)

TIPRANKS
·
29 Apr

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY), Ironwood Pharma (IRWD) and Repligen (RGEN)

TIPRANKS
·
25 Apr

Ironwood Pharmaceuticals Inc - Raises 2025 Adjusted Ebitda Guidance to Over $105 Million

THOMSON REUTERS
·
25 Apr

Ironwood Pharmaceuticals: Do Not Plan to Make Some Apraglutide Commercial Launch Planning Investments

THOMSON REUTERS
·
25 Apr

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

Business Wire
·
25 Apr

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

Business Wire
·
23 Apr

Ironwood Shares Tank on Regulatory Update for Apraglutide

Zacks
·
15 Apr

Ironwood Pharmaceuticals Cut to Equal-Weight From Overweight by Wells Fargo

Dow Jones
·
15 Apr

Wells Fargo Downgrades Ironwood Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $1 From $7

MT Newswires Live
·
15 Apr

U.S. RESEARCH ROUNDUP- CNB Financial, Disney, Triumph Group

Reuters
·
15 Apr

Wells downgrades Ironwood to Equal Weight on ‘major setback’

TIPRANKS
·
15 Apr